LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Pfizer

Pfizer

Suletud

SektorTervishoid

25.31 -1.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.24

Max

25.82

Põhinäitajad
By Trading Economics
Sissetulek	4.3B 2.7B
Müük	-3.1B 14B
P/E Sektori keskmine	19.702 51.415
Aktsiakasum	0.75
Dividenditootlus	6.7
Kasumimarginaal	18.656
Töötajad	75,000
EBITDA	4.5B 5.2B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+13.28% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	6.70% 2.34%
Järgmine tulemuste avaldamine	4. aug 2026
Järgmine dividendimakse kuupäev	12. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	24. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-2.5B 147B
Eelmine avamishind	26.98
Eelmine sulgemishind	25.31

Uudiste sentiment

By Acuity

47%

53%

147 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

22.855 / 23.85 Toetus ja vastupanu

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 11:31 UTC

Tulu

Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending

5. mai 2026, 18:12 UTC

Tulu

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 13:54 UTC

Tulu

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 12:35 UTC

Tulu

Pfizer Posts Better-Than-Expected Revenue, Profit -- WSJ

5. mai 2026, 11:06 UTC

Tulu

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates -- Barrons.com

5. mai 2026, 10:47 UTC

Tulu

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

5. mai 2026, 10:47 UTC

Tulu

Pfizer Still Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

5. mai 2026, 10:46 UTC

Tulu

Pfizer 1Q Revenue of Launched, Acquired Products Rose 22% Operationally >PFE

5. mai 2026, 10:46 UTC

Tulu

Pfizer 1Q Revenue Rose 7% Operationally Excluding Contributions From Comirnaty, Paxlovid >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer Reaffirms 2026 Guidance >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer 1Q Rev $14.5B >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer 1Q EPS 47c >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer 1Q Net $2.69B >PFE

5. mai 2026, 10:45 UTC

Tulu

Pfizer 1Q Adj EPS 75c >PFE

5. mai 2026, 10:36 UTC

Kuumad aktsiad

Stocks to Watch: Palantir, HSBC, Intel, AMD -- WSJ

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

11. märts 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

10. märts 2026, 12:50 UTC

Tulu

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10. märts 2026, 11:18 UTC

Tulu

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

9. märts 2026, 09:43 UTC

Kuumad aktsiad

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:17 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3. veebr 2026, 21:36 UTC

Tulu

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3. veebr 2026, 19:56 UTC

Tulu

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. veebr 2026, 19:46 UTC

Tulu

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3. veebr 2026, 17:35 UTC

Tulu

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. veebr 2026, 17:30 UTC

Tulu

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

13.28% tõus

12 kuu keskmine prognoos

Keskmine 29.17 USD 13.28%

Kõrge 36 USD

Madal 25 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Pfizer aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

22.855 / 23.85Toetus ja vastupanu

Bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

147 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.